Yarbrough Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Yarbrough Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,203	Closed	-$37.1K	–	214
2024 Q4	$37.1K	Hold	12,203	–	–	﹤0.01%	190
2024 Q3	$63.3K	Hold	12,203	–	–	﹤0.01%	200
2024 Q2	$31.4K	Hold	12,203	–	–	﹤0.01%	197
2024 Q1	$60K	Hold	12,203	–	–	﹤0.01%	195
2023 Q4	$107K	Hold	12,203	–	–	0.01%	202
2023 Q3	$140K	Hold	12,203	–	–	0.01%	200
2023 Q2	$309K	Hold	12,203	–	–	0.02%	177
2023 Q1	$393K	Buy	+12,203	New	+$380K	0.03%	147

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Yarbrough Capital's RVNC Position: Q1 2025 in Review

Yarbrough Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 12,203 shares — an estimated $37.1K sold.

Yarbrough Capital first reported a position in RVNC in Q1 2023 and held it in 8 quarters. The position peaked at $393K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Yarbrough Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Yarbrough Capital sold 12,203 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $37.1K.
Yarbrough Capital first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 8 quarters.
Yarbrough Capital's Revance Therapeutics, Inc. position peaked at $393K in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Yarbrough Capital's 13F filing for Q1 2025, filed 14 Apr 2025.